XueyanChenMDPh.D

PubMed

• Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute...
  John K Choi, Wenbin Xiao, Xueyan Chen, Sanam Loghavi, Kojo S Elenitoba-Johnson, Kikkeri N Naresh, L Jeffrey Medeiros, Magdalena Czader> ;Modern Pathology. 2024 Mar 7
• 1 citations
  Flow Cytometric Assessment of Myelodysplastic Syndromes/Neoplasms.
  Xueyan Chen, Ulrika Johansson, Sindhu Cherian> ;Clinics in Laboratory Medicine. 2023 Dec 1
• Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms.
  Xueyan Chen, Wenjing Wang, Jeffrey Yeh, Yu Wu, Vivian G Oehler, Yajuan J Liu, Naresh, K.> ;The Journal of Molecular Diagnostics. 2023 Dec 1
• 7 citations
  Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
  Xueyan Chen, Qi Gao, Mikhail Roshal, Sindhu Cherian> ;Cytometry. Part B, Clinical Cytometry. 2023 May 1
• 3 citations
  Mature B- and plasma-cell flow cytometric analysis: A review of the impact of targeted therapy.
  Qi Gao, Xueyan Chen, Sindhu Cherian, Mikhail Roshal> ;Cytometry. Part B, Clinical Cytometry. 2023 May 1
• 10 citations
  Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.
  Gisriel, S., Yuan, J., Braunberger, R., Maracaja, D., Chen, X., Wu, X., McCracken, J., Chen, M., Xie, Y., Brown, L., Li, P., Zhou, Y., Sethi, T., McHenry, A., Hauser, ...> ;Modern Pathology. 2022 Oct 1
• 1010 citations
  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
  Khoury, J., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J., Bejar, R., Berti, E., Busque, L., Chan, J., Chen, W., Chen, X., Chng, W., Choi, J., Colmenero,...> ;Leukemia. 2022 Jul 1
• 5 citations
  Mast cell sarcoma: clinicopathologic and molecular analysis of 10 new cases and review of literature.
  Nana P Matsumoto, Ji Yuan, Jun Wang, Qi Shen, Xueyan Chen, Young Kim, Craig W Zuppan, Chung-Che Chang, Wei Cui, Dong Chen, Min Shi, Savanah D Gisriel, Mingyi Chen, Min...> ;Modern Pathology. 2022 Jul 1
• 6 citations
  "Blasts" in myeloid neoplasms - how do we define blasts and how do we incorporate them into diagnostic schema moving forward?
  Xueyan Chen, Jonathan R Fromm, Naresh, K.> ;Leukemia. 2022 Feb 1
• 1 citations
  Clinicopathologic Findings in Patients With Initial Diagnosis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) in Colorectal Muc...
  Lorinda Soma, Stephen D. Smith, Prathima Reddy, Kerstin L. Edlefsen, David Wu, Sindhu Cherian, Xueyan Chen, Yi Zhou, Deepti M. Reddi, Jonathan R. Fromm> ;American Journal of Clinical Pathology. 2021 Aug 31
• 9 citations
  Evaluation of Preclinical Activity of Isatuximab in Patients with Acute Lymphoblastic Leukemia.
  Anlai Wang, Zhili Song, Gang Zheng, Céline Nicolazzi, Jonathan R. Fromm, Elvis Shehu, Srimathi Srinivasan, Xueyan Chen, Chen Zhu, Marielle F. Chiron Blondel, Francisco...> ;Molecular Cancer Therapeutics. 2021 Aug 10
• 5 citations
  Role of Minimal Residual Disease Testing in Acute Myeloid Leukemia.
  Xueyan Chen, Sindhu Cherian> ;Clinics in Laboratory Medicine. 2021 Jul 2
• 19 citations
  Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
  Xueyan Chen, Megan Othus, Brent L. Wood, Roland B. Walter, Pamela S. Becker, Mary-Elizabeth M. Percival, Janis L. Abkowitz, Frederick R. Appelbaum, Elihu H. Estey> ;Leukemia & Lymphoma. 2021 Apr 16
• 12 citations
  Genetic basis for iMCD-TAFRO
  Akihide Yoshimi, Tanya M. Trippett, Nan Zhang, Xueyan Chen, Alexander V Penson, Maria E. Arcila, Janine D. Pichardo, Jeeyeon Baik, Allison Sigler, Hironori Harada, Dav...> ;Oncogene. 2020 Feb 12
• 43 citations
  Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy.
  Joshua A. Hill, Elizabeth M Krantz, Kevin A. Hay, Sayan Dasgupta, Terry Stevens-Ayers, Rachel A Bender Ignacio, Merav Bar, Joyce Maalouf, Sindhu Cherian, Xueyan Chen, ...> ;Blood Advances. 2019 Nov 26
• 65 citations
  Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
  Mazyar Shadman, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Filippo Milano, Ang Li, Alexandre V. Hirayama, Mohamed L. Sorror, Sindhu Cherian, Xueyan Chen, Ryan ...> ;Blood Advances. 2019 Oct 22
• 9 citations
  Immunophenotypic Features of Myeloid Neoplasms Associated with Chromosome 7 Abnormalities.
  Xueyan Chen, Brent L. Wood, Sindhu Cherian> ;Cytometry. Part B, Clinical Cytometry. 2019 Jul 1
• 201 citations
  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
  Alexandre V. Hirayama, Jordan Gauthier, Kevin A. Hay, Jenna M. Voutsinas, Qian Wu, Ted Gooley, Daniel Li, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawki...> ;Blood. 2019 Apr 25
• 247 citations
  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
  Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama, Jenna M. Voutsinas, Qian Wu, Daniel Li, Ted Gooley, Sindhu Cherian, Xueyan Chen, Barbara S. Pender, Reed M. Hawki...> ;Blood. 2019 Apr 11
• 20 citations
  Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
  Yi Zhou, Andres Moon, Eric Hoyle, Jonathan R. Fromm, Xueyan Chen, Lori Soma, Stephen J. Salipante, Brent L. Wood, David Wu> ;Cytometry. Part B, Clinical Cytometry. 2019 Jan 1
• 22 citations
  New insights into the evolution of wheat avenin-like proteins in wild emmer wheat (Triticum dicoccoides).
  Yujuan Zhang, Xin Hu, Shahidul Islam, Maoyun She, Yanchun Peng, Zitong Yu, Steve Wylie, Angéla Juhász, Mirza Dowla, Rongchang Yang, Jingjuan Zhang, Xiaolong Wang, Bern...> ;Proceedings of the National Academy of Sciences of the United States of America. 2018 Dec 26
• 6 citations
  Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations.
  James Y. Dai, Xiaoyu Wang, Matthew F. Buas, Chengjuan Zhang, Jie Ma, Bing Wei, Yin Li, Baosheng Zhao, Teresa S Hyun, Xueyan Chen, Keith R Loeb, Robert D. Odze, Lena Ya...> ;Communications Biology. 2018 Oct 24
• 8 citations
  Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.
  Cecilia C. S. Yeung, Scott McElhone, Xue Yan Chen, David P Ng, Barry E. Storer, H. Joachim Deeg, Min Fang> ;Modern Pathology. 2018 Apr 1
• 24 citations
  Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies.
  Allison R. Greenplate, Kai Wang, Rati Tripathi, Norma Alonzo Palma, Siraj M. Ali, Phil Stephens, Vincent A. Miller, Yu Shyr, Yan Guo, Nishitha Reddy, Lina Kozhaya, Der...> ;JCO Precision Oncology. 2018 Feb 13
• 25 citations
  Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis
  Xueyan Chen, Sindhu Cherian> ;Clinics in Laboratory Medicine. 2017 Dec 1
• Join now to see all

Abstracts/Posters

• Comprehensive Evaluation and Validation of a Next-Generation Sequencing Assay for Minimal Residual Disease Detection in T-Lymphoblastic Leukemia/Lymphoma
  Xueyan Chen, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Myelodysplastic Syndrome with Excess Blasts and Secondary Acute Myeloid Leukemia: Same Disease with Different Blast Count 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018